Nutritional Growth Solutions Limited Secures AU$2 Million Capital Raise to Drive Expansion
Highlights:
Nutritional Growth Solutions Limited (ASX: NGS) secured AU$2 million (at the time of writing) through a placement of 100 million new shares at AU$0.02 each, subject to shareholder approval in December 2025.
Funds will be used for sales and marketing initiatives, inventory expansion, corporate expenses, and to pursue both organic and inorganic growth opportunities.
Taurus Capital Group Pty Ltd acted as the lead manager, earning a 6% placement fee and 25 million options exercisable at AU$0.025 over three years, pending shareholder approval.
Capital Raise to Support Growth Strategy
Nutritional Growth Solutions Limited (ASX: NGS), a U.S.-based health and nutrition company, announced it has received firm commitments from sophisticated and professional investors to raise AU$2 million (at the time of writing) through a share placement. The funds will be raised at AU$0.02 per share, with up to 100 million new fully paid ordinary shares to be issued, subject to shareholder approval at an Extraordinary General Meeting (EGM) scheduled for December 2025.
The capital raise aims to strengthen NGS’s financial position as it continues to expand its nutritional product portfolio and global distribution footprint. The company emphasized that none of the participants in this placement are related parties.
Proceeds Target Sales, Marketing, and Growth
NGS plans to allocate the funds strategically across multiple initiatives, including sales and marketing efforts to accelerate brand growth, inventory build-up to meet portfolio and distribution expansion, and general corporate and transactional expenses. Additionally, a portion of the capital will be directed toward pursuing both organic and inorganic growth opportunities as they arise in the evolving wellness and nutrition markets.
Lead Manager and Fee Structure
The placement is being led by Taurus Capital Group Pty Ltd, which will receive a 6% placement fee in cash for its services. Furthermore, the lead manager will be issued 25 million options with an exercise price of A$0.025, expiring three years from the date of issue—subject to shareholder approval at the upcoming meeting.
Outlook
This capital raise marks an important milestone for Nutritional Growth Solutions Limited as it seeks to reinforce its growth trajectory and expand its market reach. The additional funding is expected to enhance operational capabilities, fuel sales momentum, and position the company for sustainable long-term value creation.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Nutritional Growth Solutions Limited Secures AU$2 Million Capital Raise to Drive Expansion
Highlights:
Nutritional Growth Solutions Limited (ASX: NGS) secured AU$2 million (at the time of writing) through a placement of 100 million new shares at AU$0.02 each, subject to shareholder approval in December 2025.
Funds will be used for sales and marketing initiatives, inventory expansion, corporate expenses, and to pursue both organic and inorganic growth opportunities.
Taurus Capital Group Pty Ltd acted as the lead manager, earning a 6% placement fee and 25 million options exercisable at AU$0.025 over three years, pending shareholder approval.
Capital Raise to Support Growth Strategy
Nutritional Growth Solutions Limited (ASX: NGS), a U.S.-based health and nutrition company, announced it has received firm commitments from sophisticated and professional investors to raise AU$2 million (at the time of writing) through a share placement. The funds will be raised at AU$0.02 per share, with up to 100 million new fully paid ordinary shares to be issued, subject to shareholder approval at an Extraordinary General Meeting (EGM) scheduled for December 2025.
The capital raise aims to strengthen NGS’s financial position as it continues to expand its nutritional product portfolio and global distribution footprint. The company emphasized that none of the participants in this placement are related parties.
Proceeds Target Sales, Marketing, and Growth
NGS plans to allocate the funds strategically across multiple initiatives, including sales and marketing efforts to accelerate brand growth, inventory build-up to meet portfolio and distribution expansion, and general corporate and transactional expenses. Additionally, a portion of the capital will be directed toward pursuing both organic and inorganic growth opportunities as they arise in the evolving wellness and nutrition markets.
Lead Manager and Fee Structure
The placement is being led by Taurus Capital Group Pty Ltd, which will receive a 6% placement fee in cash for its services. Furthermore, the lead manager will be issued 25 million options with an exercise price of A$0.025, expiring three years from the date of issue—subject to shareholder approval at the upcoming meeting.
Outlook
This capital raise marks an important milestone for Nutritional Growth Solutions Limited as it seeks to reinforce its growth trajectory and expand its market reach. The additional funding is expected to enhance operational capabilities, fuel sales momentum, and position the company for sustainable long-term value creation.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au